Atara Bio

Atara Biotherapeutics $ATRA develops next-gen #CART therapies & off-the-shelf allogeneic #TCellRx #immunotherapy for cancer & #MS #EBV+ #PTLD #celltherapy

[Atara Bio @Atarabio]

Today we announced our first quarter 2024 financial results and operational progress. The latest news is available here: https://t.co/fySF5Mh4zB
#celltherapy #allogeneic #CART $ATRA

[Atara Bio @Atarabio]

Today we announced our fourth quarter and full year 2023 operational progress and financial results. The latest news is available here: https://t.co/0NGiaf6pcc
#celltherapy #allogeneic #CART $ATRA

[Atara Bio @Atarabio]

Tune in now for a cell therapy panel with CEO Pascal Touchon at Cowen Inc.’s 44th Annual Healthcare Conference. A link to the live webcast can be found in the investor section of our website: https://t.co/9OkRQ9Vqgq

[Atara Bio @Atarabio]

We are excited to announce that Atara’s Investigational New Drug application for ATA3219, our investigational, allogeneic, anti-CD19 #CAR #Tcell therapy, has received FDA clearance in systemic lupus erythematosus (#SLE) with #lupusnephritis. Read more: https://t.co/u0NmI1bhwR

[Atara Bio @Atarabio]

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://t.co/WZqRn7uCgd

[Atara Bio @Atarabio]

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://t.co/GsUWrBCioi
#CART #JPM24

[Atara Bio @Atarabio]

At this year's @ASH_hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://t.co/niBlzQV5Q9 #ASH23

[Atara Bio @Atarabio]

@ASH_hematology's #ASH23 is underway, and Atara is joining! If you're in San Diego, stop by our booth #1456 to learn more about our next-generation allogeneic #CART #EBV approach.

[Atara Bio @Atarabio]

We’re heading to San Diego for #ASH23 to share positive new preclinical B-cell malignancy data for ATA3431, an investigational next-generation #allogeneic CD20/CD19-targeted CAR #EBV T-cell therapy. Be sure to stop by and check out our poster on Dec. 11.

[Atara Bio @Atarabio]

Happening today, we are joining @myESMO to present new data from a combined analysis evaluating tab-cel® for #EBV+ CNS #PTLD during an oral session. Learn more: https://t.co/Kzo6OUzpcg #ESMOImmuno23

[Atara Bio @Atarabio]

We're gearing up to join researchers and clinicians at #ESMOImmuno23. We look forward to presenting new clinical data during an oral session evaluating investigational tab-cel® for #EBV+ CNS #PTLD. Learn more: https://t.co/SHmE8uz7PG

[Atara Bio @Atarabio]

Today we announced Atara entered an expanded global tab-cel® partnership with Pierre Fabre Laboratories. Tune in to our conference call and live webcast at 9:00 a.m. EDT to hear more and other third quarter 2023 corporate updates. https://t.co/UUYcUqKatU

#EBV #MS #CART #PTLD

[Atara Bio @Atarabio]

While autologous T-cell therapies have been life-changing for many patients, allogeneic approaches hold the promise of personalized, off-the-shelf treatments manufactured at scale, stored and ready for rapid delivery. Learn more about Atara’s approach: https://t.co/sZvAtSNIl1

[Atara Bio @Atarabio]

Atara’s EBV T-cell platform has the potential to address a wide range of EBV-driven diseases or other serious diseases through the incorporation of engineered #CARs. Learn more about our versatile platform: https://t.co/sZvAtSNIl1

[Atara Bio @Atarabio]

Today, our CSO & CTO, Cokey Nguyen, joins @alliancerm's #CGMesa23 to discuss how the world’s first-ever approval of an allogeneic T-cell therapy helped galvanize the #celltherapy field, paving the way to make further inroads into our fight against cancer and autoimmune disorders.

[Atara Bio @Atarabio]

On #WorldMentalHealthDay, we emphasize our commitment to promoting mental well-being within our organization and beyond. Our Spring Health Mental Wellness Benefit empowers Atarians with the resources to focus on our mission of developing therapies to transform patients' lives.

[Atara Bio @Atarabio]

At Atara, we are using allogeneic Epstein-Barr virus (#EBV) T cells as a platform to develop investigational therapies for cancer and autoimmune diseases. Learn more about our pipeline: https://t.co/9yUTxWY4Wx

[Atara Bio @Atarabio]

#DYK: A natural, evolutionarily honed immune response to #EBV can be repurposed to fight disease? At Atara, we harness immune cells from healthy donors as the basis of our platform to manufacture allogeneic #EBV T cells. More: https://t.co/sZvAtSNIl1

[Atara Bio @Atarabio]

Everything we do at Atara revolves around our mission to transform patients' lives. On #RareCancerDay, we join @RareDiseases and this resilient community to honor those affected by uncommon #cancers and shed light on the challenges faced by people living with #rarecancers.

[Atara Bio @Atarabio]

Allogeneic cell therapies can be stored in advance of patient need, ready for delivery within days. Learn more about our off-the-shelf approach: https://t.co/56hQAFmhn5